Michael Kleerekoper (August 18, 1944 to May 10, 2018): In Relentless Pursuit of a Better Way

Le résumé fourni par la source

Michael Kleerekoper On May 10, 2018, the bone and mineral community lost Michael Kleerekoper, one of its gems. Michael was born in Leeds, England, to Lilly (Biber) and Joseph Kleerekoper. When he was a toddler, the family moved to Sydney, Australia. Michael received his BSc with honors in 1967 and his MBBS (the MD equivalent but never so acknowledged; a prototypical Michaelism!) in 1970. His interest and curiosity in our field was catalyzed under the tutelage of another late giant of our field, Dr Sol Posen. Moving to St. Louis for his endocrinology and metabolism fellowship, Michael was then mentored by the late, great Lou Avioli, a founder of the ASBMR, as well as by John Haddad and Steve Teitelbaum. He also worked closely then with Roberto Civitelli and Roberto Pacifici. After his formative years at Washington University, Michael moved to Henry Ford Hospital, where he enjoyed a remarkably productive career working with Drs Boy Frame, A Michael Parfitt, and one of us (SDR). During his time at the Henry Ford Hospital, Michael trained a large number of future clinicians and basic scientists. With other luminaries there at the time, Michael's contributions, which spanned over 15 years, contributed significantly to our understanding of bone biology and mineral homeostasis. Examples include developing and applying assays for parathyroid hormone and 25-hydroxyvitamin D; reviving interest in skeletal histomorphometry as a clinical tool; and legendary contributions to our understanding of primary hyperparathyroidism and osteoporosis. In 1993, Michael moved to Wayne State University, where he served as director of research for bone and mineral metabolism and gerontology for the School of Medicine. Later, he became chief of the Endocrinology Division at University of Toledo Medical School. Michael was a clinician, an educator, a passionate investigator, and an outside-the-box thinker. He questioned the obvious, challenged long-standing traditions, and was never satisfied with conventional answers. He was an erudite reader, published prolifically, and served on editorial boards of several prestigious journals including this one. He was active in the American Association of Clinical Endocrinologists from its inception, and in 2006 he received its distinguished honor, Master of the American College of Endocrinology (MACE). Michael's contributions to basic research included the cellular origin of liver alkaline phosphatase activity demonstrating that it was not hepatocytes but rather biliary tract lining cells. His contributions to clinical conundrums included the question of whether all patients with primary hyperparathyroidism needed surgery, a question that paved the way for a randomized clinical trial of parathyroidectomy versus no surgery. He was an important contributor to the first clinical trials of sodium fluoride in osteoporosis. His contributions to translational science were also noteworthy, highlighted by helping to establish microarchitectural deterioration as a feature of the osteoporotic state and subsequently as a key element in the definition of osteoporosis. Michael was always forthright, direct, and spoke his mind, qualities that were not always endearing but that always provoked respect. Below are personal reflections of Dorothy Nelson, his wife, as well as professional colleagues and his close friends who knew the man up close. I am grateful to Michael for introducing me to clinical research and having taught me how both basic and clinical research can be pursued at the same time. He was always supportive and yet always critically relevant. He was a meticulous researcher, an avid thinker, and a dear friend. Our friendship bonded more tightly during a trip to India in 1991 as a part of a nationwide Endocrinology Symposia tour. He was eager to educate medical students, postgraduates, and endocrinology fellows in India. Of course, Michael always liked attention and wanted to have the last word, but again who doesn't! Michael and I spent long hours (the jet lag helped!) discussing and, yes, arguing at times how our field should move forward. As one who “grew up” with Michael for more than four decades, I sorely miss his wit, grit, and grace. With the previous passing of Boy Frame, Harold Frost, and Michael Parfitt and now with the loss of Michael, I feel a keen sense of profound loss. We have lost a friend who was as engaging as he was beneficially provocative, pushing us always to be clear, to be rigorous, and to be passionate about our work. With self-confidence that bolstered the rest of us, Mike never shied away from a knotty issue and made us, in kind, reach for knowledge above the low-hanging fruit. Years ago, Mike wanted to create a specialty that would be recognized as “osteology,” thinking correctly that the discipline of metabolic bone diseases was broad and deep enough to require the kinds of standards accorded other recognized specialties in internal medicine. While that effort did not succeed officially, it did succeed in real terms. Mike's proposal made us think of ourselves as true specialists dealing with diseases that matter. He helped us to think of ourselves in ways that defined us more realistically and, yes, in a much more relevant manner. Mike was a true iconoclast. We loved him for a refreshing view of virtually anything that was put before his keen intellect. Always filled with opinions that he freely expressed, he was also careful to distinguish them from facts, a standard to which he held us all. His contributions to new knowledge in our field are legendary; placing that new knowledge into the proper clinical context was his special gift. We will miss you, Mike, but remember what you taught over and over again: Be passionate about our field; teach our next generation with the same passion as our mentors did; don't settle for incomplete insight; and love life as we love our field. Although some thought Michael was from South Africa, those with a keen ear for accents would know that Michael (born in England) was really from Australia, where he graduated with honors from the University of Sydney and received his medical education and internal medicine training. He moved to St. Louis for an endocrinology fellowship at Washington University, then to Detroit, where he lived for almost half a century. A consummate academic physician, Michael had numerous teaching positions, served as reviewer and editorial board member for a number of journals, was active in all the right professional societies (including the American Association of Clinical Chemistry and the American College of Endocrinology, which honored him as a MACE [Master]). He authored almost 300 articles, editorials, letters, books and chapters, proceedings and abstracts, always bringing forth with these publications keen insights and original thinking. I drew close to Michael Kleerekoper early in my career as he was unmistakably noticeable at our national and international bone meetings. As he frequently went to the microphone, and thus even more noticeable, I observed a man whose tone was sometimes strident, whose opinions were always strong, and whose bearing was frankly a bit intimidating (actually more than just a bit). Waiting to go to the airport after one or another meeting, not knowing each other very well, he invited me to join him for a beer. The ensuing wonderful conversation began a lengthy friendship that included our spouses (his wife, Dorothy Nelson, greets me with “hello, Nelson” and I say the same back to her). Michael was one of a kind. His passing leaves a void, professionally and personally, that I doubt can be filled. Michael was my friend as well as my close professional colleague. From his early days at Henry Ford Hospital, where he was a key member of the large group of metabolic bone disease giants that made Henry Ford an internationally respected institution in “bone,” to his final years at the Medical College of Ohio, he molded young min

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.